REVIEW

Thyroid hormone receptor localization in target tissues

Cyril S Anyetei-Anum, Vincent R Roggero and Lizabeth A Allison
Department of Biology, College of William and Mary, Williamsburg, Virginia, USA
Correspondence should be addressed to L A Allison: laalli@wm.edu

Abstract

The thyroid hormone receptors, TRα1, TRβ1 and other subtypes, are members of the nuclear receptor superfamily that mediate the action of thyroid hormone signaling in numerous tissues to regulate important physiological and developmental processes. Their most well-characterized role is as ligand-dependent transcription factors; TRs bind thyroid hormone response elements in the presence or absence of thyroid hormone to facilitate the expression of target genes. Although primarily residing in the nucleus, TRα1 and TRβ1 shuttle rapidly between the nucleus and cytoplasm. We have identified multiple nuclear localization signals and nuclear export signals within TRα1 and TRβ1 that interact with importins and exportins, respectively, to mediate translocation across the nuclear envelope. More recently, enigmatic cytoplasmic functions have been ascribed to other TR subtypes, expanding the diversity of the cellular response to thyroid hormone. By integrating data on localization signal motifs, this review provides an overview of the complex interplay between TR’s dynamic transport pathways and thyroid hormone signaling activities. We examine the variation in TR subtype response to thyroid hormone signaling, and what is currently known about regulation of the variety of tissue-specific localization patterns, including targeting to the nucleus, the mitochondria and the inner surface of the plasma membrane.

Introduction

Thyroid hormone is essential for many diverse processes in nearly all vertebrate tissues, and abnormal thyroid hormone signaling underpins several human diseases (Laudet & Gronemeyer 2002, Chen et al. 2013, Kim & Cheng 2013, Mullur et al. 2014, Mondal et al. 2016, Mendoza & Hollenberg 2017, van der Spek et al. 2017). Much of thyroid hormone action is mediated by the thyroid hormone receptors (TRs), members of the nuclear receptor superfamily that act as ligand-dependent transcription factors. By modulating the transcription of target genes in response to ligand, TRs play key physiological roles in the regulation of many aspects of development, growth and metabolism, including the regulation of mitochondrial activity (Flamant & Gauthier 2013, Pascual & Aranda 2013, Bernal 2017, Skah et al. 2017, Vella & Hollenberg 2017, Wrutniak-Cabello et al. 2017). Thyroid hormone signaling is typically classified into two distinct pathways, nongenomic and genomic; however, these designations do not fully capture the subtleties of thyroid hormone action. To address the complexity of thyroid hormone signaling, a more precise nomenclature has recently been formulated (Flamant et al. 2017). In this new classification scheme, four types of thyroid hormone signaling are defined: type 1 is the canonical pathway in which liganded TR binds directly to DNA; type 2 describes liganded TR tethered to chromatin-associated proteins,
but not bound to DNA directly; type 3 suggests that liganded TR can exert its function without recruitment to chromatin in either the nucleus or cytoplasm; and type 4 proposes that thyroid hormone acts at the plasma membrane or in the cytoplasm without binding TR, a mechanism of action that is emerging as a key component of thyroid hormone signaling (Kalyanaraman et al. 2014, Davis et al. 2016).

The biological effect of thyroid hormone in a given tissue depends on a number of factors: the amount of available hormone, the levels of different TR subtypes and their post-translational modifications, the type of heterodimerization partner and their interaction with corepressors and coactivators (Morte & Bernal 2014). In addition, accurate translocation of TRs from their synthesis in the cytosol to their ultimate destination is essential for maintaining proper cellular functions and activities (Bonamy et al. 2005, Bonamy & Allison 2006, Fernandez-Majada et al. 2007, Bondzi et al. 2011, Wang & Li 2014).

The thyroid hormone receptors are remarkably dynamic proteins. Although primarily residing in the nucleus, TRα1 and TRβ1 shuttle rapidly between the nucleus and cytoplasm, and recent characterization of TRα1 isoforms with cytoplasmic functions adds a surprising twist to the intricacies of the receptor's subcellular trafficking. The fine balance between nuclear import and export of TRs has emerged as a critical control point for modulating thyroid hormone-responsive gene expression (Subramanian et al. 2015, Roggero et al. 2016), while an additional layer of complexity is added by multiple modular, often overlapping, functional domains. General understanding of nuclear localization signal (NLS) and nuclear export signal (NES) structure, mitochondrial and membrane targeting signals, and how these motifs are regulated will assist in refining the understanding of the mechanism of action of TRs. In this review, we will focus on the mechanisms regulating the journey of TR from its site of synthesis in the cytoplasm to its final localization in target tissues, and how the receptor integrates gene expression across multiple levels in the cellular response to hormone. Before considering the cellular response to thyroid hormone, it is important to first examine the pathway by which thyroid hormone reaches target tissues and gains access to its intracellular receptors.

**Thyroid hormone signaling**

Thyroid hormone is produced through a feedback loop that includes the hypothalamus, pituitary and thyroid gland, commonly referred to as the hypothalamic–pituitary–thyroid (HPT) axis (Medici et al. 2015, Mendoza & Hollenberg 2017). The HPT axis involves a series of signal transduction cascades, where a signal sent from the hypothalamus eventually arrives at the thyroid gland, triggering release of thyroid hormone. In the circulatory system, the majority of total 3,5,3′,5′-tetraiodothyronine (thyroxine, T4) and 3,5,3′,5″-tetraciodothyronine (T3) are bound with three different thyroid hormone carrying proteins: thyroxine-binding globulin, transthyretin and human serum albumin (Pappa et al. 2015, Mondal et al. 2016). Upon reaching the target tissue, thyroid hormones enter cells via uptake through specific membrane transporters, including the monocarboxylate transports MCT8 and MCT10 (Abe et al. 2012, Bernal et al. 2015). The most extensively characterized transporter, MCT8, transports thyroid hormone exclusively and preferentially binds T3; however, secondary thyroid hormone transporters have been described that can compensate for loss of MCT8 expression, including the heterodimeric L-type amino acid transporters (LATs), LAT1 and LAT2, and the organic anion-transporting polypeptide (OATP) family (Mendoza & Hollenberg 2017).

Once in the cell, the intracellular concentration of thyroid hormone can be modified by the action of a suite of deiodinases. The prohormone T4 can be converted to the physiologically active hormone T3, or inactivated via conversion to 3,3′,5′-triiodothyronine (reverse T3, rT3) within the cell. T3 and rT3 can be modified to form the physiologically active 3,5′-diiodothyronine (T2) or the inactive 3,3′-diodothyronine (3,3′-T2), respectively, to protect tissues from excess hormone (Dentice et al. 2013, Orozco et al. 2014, Mondal et al. 2016). Whether T3 is directly involved in mediating gene expression remains a subject of debate. T4 is thought to primarily influence gene expression indirectly by cross-talk with other cell signaling pathways at the plasma membrane (Davis et al. 2016); however, there also is accumulating evidence that T3 can directly modulate gene expression, dependent on the TR subtype and other cellular cofactors (Galton 2017). T3 is directly involved in mediating gene expression by binding to TR in either the cytoplasm or nucleus of the cell (Bunn et al. 2001). The intricate balance between thyroid hormone production and deiodination is critical for the regulation of TR-mediated gene expression, and the dysregulation of this process may contribute to type II diabetes mellitus, obesity, cardiovascular disease and some types of cancer (Ruiz-Llorente et al. 2011, Brent 2012, Kim & Cheng 2013).

In addition to the type 1 canonical response mediated by nuclear TRs, thyroid hormone also has effects not
exerted through the nuclear TRs; such effects were puzzled over early on to explain observations that thyroid hormone can, in some cases, initiate cellular responses that are too rapid to be attributed to transcription and translation (Davis et al. 2016, Flamant 2016). Although detailed coverage of type 4 actions of thyroid hormone is beyond the scope of this review, it is worth noting the existence of a hormone receptor that is associated with the plasma membrane structural protein αVβ3 integrin, a regulator of cell–cell and cell–extracellular matrix interactions (Martin et al. 2014, Mullur et al. 2014, Cvoro et al. 2016, Davis et al. 2016, Lin et al. 2016). This receptor binds T3 and T4 and stimulates certain cellular responses, such as the remodeling of the actin cytoskeleton that is a vital component of brain development in neurons and glial cells (Leonard & Farwell 1997), and changes in the morphology of breast cancer cells (Flamini et al. 2017). The αVβ3 integrin-associated receptor has two thyroid hormone-binding sites, S1 and S2, which lead to the activation of phosphatidylinositol 3-OH kinase (PI3K) and ERK1/2 signaling pathways, respectively. The receptor is structurally unrelated and has no sequence homology to nuclear TR and, although it could be referred to as a ‘thyroid hormone receptor,’ this nomenclature should be avoided to prevent misconceptions about the nature of this noncanonical receptor. Type 3 signaling, mediated by transcriptionally inactive cytoplasmic TR isoforms, will be addressed later in this review.

Nuclear localization and function of thyroid hormone receptors

The type 1 genomic effects of TRs are twofold; TRs can act as repressors of specific genes in the absence of ligand and activators of these same genes in the presence of ligand. For some genes, the reverse is the case: unliganded TR acts as an activator, while liganded TR is a repressor. This dual role of TRs implies constitutive nuclear localization. Many studies early on in the field supported this restricted subcellular distribution for TR (Kumara-Siri et al. 1986, Macchia et al. 1992, Lee & Mahdavi 1993, Andersson & Vennstrom 1997, Zhu et al. 1998, Zhang & Lazar 2000). However, we and others have shown that even though TRα1 and TRβ1 appear to be predominantly nuclear at steady state, in fact, the receptors are undergoing rapid nucleocytoplasmic shuttling in both the presence and absence of T3 (Baumann et al. 2001, Bunn et al. 2001), movement which can be visualized by heterokaryon assays or fluorescence recovery after photobleaching (Grespin et al. 2008, Subramanian et al. 2015). Detailed investigation of TRs has revealed distinct, dynamic localization patterns for some variants. Analysis of the intracellular localization of TRs by biochemical fractionation, immunocytochemistry or indirect immunofluorescence assays has proved challenging overall, because of a lack of validated isoform-specific antibodies, and the difficulty in detecting endogenous TR subtypes that are less abundant in cells. Many studies have thus relied on transient transfection assays and expression of fluorescent protein-tagged TRs. With regards to nuclear localization, in our hands, there is no indication that overexpressing TRs leads to a more cytoplasmic localization by saturating the capacity of cells to transport proteins into the nucleus or that fluorescent protein tags alter localization. For example, in transfected NIH-3T3 (mouse) cells or HeLa (human) cells, neither of which express detectable levels of endogenous TR, both exogenous GFP-tagged TRα1 and untagged TRα1 detected by antibody staining show a primarily nuclear distribution at steady state (Bunn et al. 2001, Bonamy et al. 2005).

Thyroid hormone receptor subtypes

The thyroid hormone receptors are well conserved throughout vertebrate evolution, originating from a single TR gene early in animal evolution (Manzon et al. 2014); and there is evidence for nuclear TR-mediated responses to thyroid hormone in non-vertebrate lineages, including molluscs, echinoderms, cephalochordates and ascidians (Laudet & Gronemeyer 2002, Darras et al. 2011, Huang et al. 2015, Taylor & Heyland 2017). The vertebrate thyroid hormone receptors are encoded by two genes located on different chromosomes, NR1A1 and NR1A2, although due to ancestral gene duplication, some nonmammalian vertebrate species, including teleost fish, have two TRα-encoding genes (Galay-Burgos et al. 2008, Darras et al. 2011). From these loci, a surprisingly diverse set of TR proteins are produced, through alternative splicing, alternative promoter usage and internal initiation codons. Intense investigation of rodent and human TRs continues to reveal new subtypes, while the number of subtypes identified in other species, as of yet, is more restricted (Buchholz et al. 2006, Kanaho et al. 2006, Nelson & Habibi 2008, Politis et al. 2018). For example, chickens and ducks have at least three subtypes (TRα, TRβ2, TRβ0) (Bishop et al. 2000); zebrafish produces two TRβ variants and at least three TRα isoforms that all act as functional nuclear receptors (Darras et al. 2011); two distinct TRα transcripts and one TRβ transcript have
been isolated from the American alligator (Helbing et al. 2006); and the Atlantic halibut has two TRα and two TRβ isoforms (Galay-Burgos et al. 2008). The main focus of this review is on the well-characterized mammalian receptors, in particular TRα1 and TRβ1.

Not all of the mammalian TR proteins produced act as nuclear receptors, however, and the physiological significance of many of the nonreceptor isoforms remains a subject of investigation (Flamant & Gauthier 2013, Mullur et al. 2014, Vella & Hollenberg 2017). What is currently known about the intracellular localization and function of the mammalian TRs is summarized in Table 1, and further described herein. The predominant isoforms generated by alternative splicing mechanisms include the bona fide nuclear receptors TRα1, TRβ1, TRβ2, TRβ3 and TRβ4 (Tagami et al. 2010, Moriyama et al. 2016); and the nonreceptor TR variants that lack LBD-binding ability, TRα2, TRα3 and TRα-ΔE6 (Casas et al. 2006).

TRα1 has the highest expression in bone, the gastrointestinal tract, cardiac and skeletal muscle and the central nervous system; TRα2 and TRα3 are predominant in the brain, kidney, testis, brown adipose tissue and skeletal muscle (Guissouma et al. 2014, Skah et al. 2017). TRα-ΔE6 is expressed in all tissues tested and can sequester TRα1 in the cytoplasm (Casas et al. 2006). TRα2 is found consistently in mammals but not in other species. Although a dominant negative function has been attributed to mammalian TRα2, which is widely co-expressed with TRα1, the physiological relevance has remained a puzzle, particularly since it is unexplained why it would be necessary for TRα2 to counter-balance normal TR activity in mammals but not in nonmammalian species (Vennstrom et al. 2010). There is recent compelling evidence, however, that TRα2 modulates thyrotropin-releasing hormone gene expression in the hypothalamus (Guissouma et al. 2014). In addition, four truncated forms of TRα1 (full-length, 46kDa) originate from alternative internal AUG translation initiation codons in TRα1 mRNA and are named based on their molecular masses: p43 starts at the equivalent of methionine-39 (Met39) in the full-length receptor, p33 starts with Met120, p30 starts with Met122 and p28 starts with Met150 (Kalyanaraman et al. 2014, Wrutniak-Cabello et al. 2017) (Fig. 1). Finally, other truncated forms of TRα, TRαα1 and TRαα2 are produced from an internal promoter in intron 7; they contain only the C-terminus of the ligand-binding domain (LBD) and are expressed in the brain, lung and gut (Chassande et al. 1997, Davis et al. 2016). TRαα1 has been proposed as a candidate mediator of T3 binding in the cytoplasm, potentially playing a role in regulating actin polymerization (Davis et al. 2016).

TRβ1 is most abundant in the liver, kidney and the inner ear; TRβ2 is predominant in the hypothalamus, pituitary, cochlea and retina; and TRβ4 is ubiquitously expressed, with relatively high expression in the brain and kidney (Flamant & Gauthier 2013, Hahm & Privalsky 2013, Mullur et al. 2014, Vella & Hollenberg 2017). Other minor isoforms of TRβ1 (52-kDa) also exist; for example, two isoforms are alternatively translated from TRβ1 mRNA, with TRβ3 (44.6-kDa) appearing to act as a functional receptor in rat (Flamant & Gauthier 2013), and TRβ3 (32.8-kDa) functioning as a ligand-responsive

<table>
<thead>
<tr>
<th>Receptors</th>
<th>Cellular localization</th>
<th>Known or hypothetical function(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRα (NR1A1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRα1</td>
<td>Nuclear</td>
<td>Transcriptional activation/repression</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial matrix</td>
<td>Transcriptional activation/repression</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Plasma membrane</td>
<td>Signaling cascade</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial inner membrane</td>
<td>Signaling cascade</td>
</tr>
<tr>
<td>TRα2</td>
<td>Nuclear</td>
<td>Possible antagonist of TR action</td>
</tr>
<tr>
<td>TRα3</td>
<td>Nuclear</td>
<td>Possible antagonist of TR action</td>
</tr>
<tr>
<td>TRαα1</td>
<td>Unknown</td>
<td>Possible antagonist of TR action</td>
</tr>
<tr>
<td>TRαα2</td>
<td>Unknown</td>
<td>Possible antagonist of TR action</td>
</tr>
<tr>
<td>TRα-ΔE6</td>
<td>Cytoplasm</td>
<td>Inhibitor of TR activity</td>
</tr>
<tr>
<td>TRβ (NR1A2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRβ1</td>
<td>Predominantly nuclear</td>
<td>Transcriptional activation/repression</td>
</tr>
<tr>
<td>TRβ2</td>
<td>Predominantly nuclear</td>
<td>Transcriptional activation/repression</td>
</tr>
<tr>
<td>TRβ2Δ</td>
<td>Predominantly nuclear</td>
<td>Possible transcriptional regulation</td>
</tr>
<tr>
<td>TRβ3</td>
<td>Predominantly nuclear</td>
<td>Transcriptional activation/repression</td>
</tr>
<tr>
<td>TRβα3</td>
<td>Predominantly nuclear</td>
<td>Dominant negative antagonist</td>
</tr>
<tr>
<td>TRβ4</td>
<td>Predominantly nuclear</td>
<td>Weak antagonist of TR action</td>
</tr>
</tbody>
</table>

Table 1  Cellular localization and function of mammalian TRα and TRβ isoforms.
dominant negative antagonist (Williams 2000). In addition, an elongated form of TRβ2, termed TRβ2Δ, has been proposed to function as a nuclear receptor in the rat pituitary gland (Zhao et al. 2014). In this review, we will focus on the TRα and TRβ isoforms where intracellular localization and targeting signals have been investigated in more detail.

**Functional domains of the thyroid hormone receptor**

The thyroid hormone receptor consists of four modular domains that are evolutionarily conserved among the nuclear receptor superfamily (Fig. 1): a variable N-terminal A/B domain, which contains a region involved in transactivation, activation function-1 (AF-1); a central DNA-binding domain (DBD) comprised of two zinc fingers; a C-terminal LBD, which also includes dimerization interfaces and activation function-2 (AF-2); and a linker or hinge region between the LBD and DBD that contributes to DNA binding, activation function and repression, ligand binding and corepressor interactions (Nascimento et al. 2006, Pawlak et al. 2012, Mondal et al. 2016, Zhang et al. 2018). TRα1 and TRβ1 both contain AF-1 domains involved in the transcriptional response to hormone; while the TRβ2 isoform, which differs from TRβ1 in the A/B domain, has a unique hormone-independent AF-1 domain that recruits coactivators (Tomura et al. 1995, Oberste-Berghas et al. 2000).

**Ligand-binding domain conformation**

The LBD of TR is composed of 12 α-helices that form a hollow pocket lined with hydrophobic residues. The ligand-binding site is highly flexible, and the structural details underpinning receptor activation after T3 binding are complex (Schweizer et al. 2017). The twelfth helix contains the ligand-dependent activation domain, AF-2 (Figueira et al. 2011). Helix 12 forms a short pivoting structure that can adopt different conformations. In the absence of T3, helix 12 is in an extended position and the corepressor-binding groove is occupied by the corepressor nuclear receptor (CoRNR)-box helical motifs found in silencing mediator for retinoid or thyroid-hormone receptors (SMRT) and nuclear receptor co-repressor 1 (N-CoR1). Binding of T3 may induce a hormone-dependent ‘mouse-trap’ mechanism (Moras & Gronemeyer 1998, Sonoda et al. 2008, Flamant 2016), where helix 12 rotates to swing shut and close off the pocket around T3. As a result of this conformational change, a novel docking surface forms.
for interaction with LXXLL motifs (L denotes leucine; X denotes an undetermined amino acid) of a transcriptional coactivator (Rosen & Privalsky 2011). A refinement of this model suggests that TR helix 12 functions as a ‘selective gatekeeper’ that actively discriminates between different forms of corepressor even in the unliganded receptor (Rosen & Privalsky 2009); and other models propose that rearrangements in a mobile part of the LBD comprising helix 3, the loop between helix 1 and helix 2 and nearby β-sheets, play a greater role in ligand dissociation than repositioning of helix 12 (Martinez et al. 2006). Mutations that disrupt helix 12 alter corepressor specificity as well as Tα1-mediated release of corepressors (Rosen & Privalsky 2009). Recent X-ray crystallographic structural studies have revealed a second ligand-binding site in TR located between helices 9 and 11 that may interact with Tα1 (Souza et al. 2014).

Nuclear import and export signals

The nuclear transport process provides a central regulatory point for coordinating cell signaling and gene expression. Macromolecules known as nuclear pore complexes (NPCs) are the regulatory gatekeepers of the entry and exit of nuclear proteins and allow for the passive diffusion of small molecules less than 40-kDa (Li et al. 2016). NPCs are distributed throughout the nuclear envelope, embedded at sites within the luminal space between the outer and inner membrane of the nuclear envelope (Tran et al. 2014, Cautain et al. 2015). They are octagonally symmetric cylindrical structures made up of proteins termed nucleoporins or Nups, which act to anchor the NPC in the nuclear envelope and provide interaction domains for nuclear proteins to translocate through a central channel (Hayama et al. 2017). The translocation of nuclear proteins through the NPCs is typically facilitated by karyopherin β-like family members (importins and exportins), with each member performing a distinct nuclear import, export or bidirectional transport function (Chook & Suel 2011, Kimura & Imamoto 2014).

Our systematic characterization of NES and NLS motifs by site-directed mutagenesis has elucidated the mechanics of TR nuclear localization (Mavinakere et al. 2012). In-depth analysis of TRα1 and TRβ1 structure reveals that the two subtypes both contain a classical bipartite NLS, named NLS-1, residing in the hinge region, and a second monopartite NLS, termed NLS-2, located in the A/B domain of TRα1 that is absent in TRβ1 (Fig. 1) (Mavinakere et al. 2012). RNAi and coimmunoprecipitation assays show that members of the importin family of karyopherins, specifically importin 7, importin β1 and adapter importin α1 recognize these NLSs and directly mediate the nuclear import of TRs through the NPC (Roggero et al. 2016) (Fig. 2). In support of the importance of NLS-1 for efficient nuclear localization, an isof orm that lacks the hinge domain, TRα-ΔE6, has a strikingly altered localization compared with TRα1; TRα-ΔE6-GFP was shown to be predominantly expressed in the cytoplasm with minor nuclear fluorescence (Casas et al. 2006). In addition, TRβ4 is primarily localized to the nucleus, and mutation of two putative NLSs near the hinge region results in a whole cell distribution of the receptor (Moriyama et al. 2016).

In an earlier study, we showed that TRα1 exits the nucleus through two pathways, one dependent on the export factors CRM1 and calreticulin and the other CRM1 independent (Grespin et al. 2008). In a subsequent study, we also identified a novel NES in helix 12 of the LBD of TR (NES-H12). Another novel NES motif spans helix 3 and helix 6 (NES-H3/H6) (Mavinakere et al. 2012) (Fig. 1). Notably, these NES motifs are not sensitive to leptomycin B, a specific inhibitor of CRM1, suggesting that they mediate the CRM1-independent export pathway followed by TR. Follow-up work by RNAi has shown that multiple exportins

![Figure 2](http://joe.endocrinology-journals.org) Thyroid hormone receptor nucleocytoplasmic shuttling pathway. The well-characterized pathway for TRα1 is depicted. TRα1 binds to specific importins in the cytoplasm, as indicated. The TRα1–importin complex passes through a nuclear pore complex (NPC) embedded in the nuclear envelope into the nucleus, where the complex is disassembled and TRα1 binds to target genes. TRα1 exits the nucleus through the NPC in association with specific exportins or calreticulin (CRT)/CRM1. TRβ1 follows a similar nucleocytoplasmic shuttling pathway, but nuclear import is solely mediated by the importin α1/importin β1 complex.
Thyroid hormone receptor localization

C S Anyetei-Anum et al.

influence TR export, including exportins 4, 5 and 7 (Subramanian et al. 2015). Not surprisingly, the two NLSs found in TRα1 act to confer strong nuclear localization to the receptor; we hypothesize that TRβ1’s small cytosolic population (Zhu et al. 1998, Baumann et al. 2001) may reflect an altered balance of NLS and NES activity (Mavinakere et al. 2012, Zhang et al. 2018) (Fig. 3). Although multiple NLS and NES motifs exist in a variety of nuclear proteins, how these multiple signals interact collectively remains unclear (Bonaldi et al. 2003, Mavinakere et al. 2012, Umemoto & Fujiki 2012, Lu et al. 2014, Dai et al. 2015, Panayiotou et al. 2016). Once TRs are directed into the nucleus and released from importin, they can then interact with target genes to modulate gene expression in response to hormone.

Thyroid hormone receptor gene activation and silencing

A multifaceted cascade of events results in binding of TRs to thyroid hormone response elements (TREs) and culminates in the modulation of target gene expression in response to thyroid hormone (Brent 2012, Bernal & Morte 2013, Ayers et al. 2014, Vella & Hollenberg 2017). Thyroid hormone receptors often heterodimerize with the retinoid X receptor (RXR), expanding the range of T₃ responsiveness for genes within the same cell (Diallo et al. 2007, Flamant 2016). On positive TREs, corepressors, such as N-CoR1 or N-CoR2 (also known as SMRT) and histone deacetylase (HDAC), are bound in the absence of ligand to TR, leading to repression of target gene expression (Xu et al. 1999, Oberoi et al. 2011, Mendoza et al. 2017). Upon ligand binding, TR undergoes a conformational change, resulting in a new set of activator proteins bound to the receptor, such as SRC-1 (p160/steroid receptor coactivator 1) and histone acetyltransferase (HAT). This leads to changes in chromatin structure and the subsequent transcription of the target gene (McKenna et al. 1999, Soriano et al. 2011, Dasgupta & O’Malley 2014). In addition to unliganded TR bound to positive TREs, chromatin immunoprecipitation sequencing (ChIP-seq) analysis of endogenous TR in mouse liver tissue suggests that the receptor’s interaction with chromatin is highly dynamic and that it can be recruited to chromatin in a ligand-dependent manner.

Figure 3

Distinct intracellular localization patterns for TRα1 and TRβ1. HeLa cells transfected with expression plasmids for green fluorescent protein (GFP)-tagged TRα1 and TRβ1 were analyzed by fluorescence microscopy after staining for DNA with DAPI to visualize the nucleus. GFP-TRα1 predominantly localizes to the nucleus; GFP-TRβ1 also localizes to the nucleus but has a slight cytoplasmic population. Scale bar, 10 µm.
manner (Grontved et al. 2015). These findings align with an earlier report that used fluorescence recovery after photobleaching (FRAP) to show that TRβ1 moves rapidly within the nucleus and that ligand binding does not affect its mobility (Maruvada et al. 2003). A recent study in mice suggests that TR target genes respond to T₃ based on the availability of specific corepressors and coactivators, providing an explanation for tissue-specific responses to similar amounts of T₃ (Vella et al. 2014). In addition to activating transcription on positive TREs, TRs can also repress gene expression, possibly by binding to putative negative TREs in a T₃-dependent manner (Bernal & Morte 2013). In this instance, N-CoR1 and SMRT appear to play a role in determining T₃ sensitivity, suggesting that corepressors can be recruited to TR in the presence of T₃ (Aastad et al. 2011, Astapova & Hollenberg 2013, Shimizu et al. 2015). The mechanism remains unclear, however, and a recent genome-wide analysis of chromatin occupancy of TRs in neural cells does not appear to support the hypothesis that liganded TR acts directly as a transcription repressor (Chatonnet et al. 2013). Further, ChIP-seq studies in hypothyroid and hyperthyroid mouse liver cells suggest that negative regulation instead may be mediated by diminished TR recruitment in the presence of T₃ (Ramadoss et al. 2014).

**Cytoplasmic functions of the thyroid hormone receptor**

For many years, the focus in the field was on characterizing the nuclear function of TRs, but now their emerging roles in the cytoplasm also must be considered. Study of the functional domains of full-length TRα1 (p46) and the truncated isoforms p43, p33, p30 and p28 has revealed conflicting intracellular targeting signals within TRα1 that can direct the proteins to the nucleus, mitochondria or the inner surface of the plasma membrane (Mavinakere et al. 2012, Kalyanaraman et al. 2014, Wrutniak-Cabello et al. 2017) (Figs 1 and 4). TRα1 p43 and p28 are targeted to the mitochondrial matrix and mitochondrial inner membrane, respectively. The biological function of TRα1 p33 remains unknown, but p30 is post-translationally modified via palmitoylation and colocalizes with caveolin-1 at the inner surface of the plasma membrane. Upon binding T₃, the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling cascade is activated and stimulates the proliferation and survival in multiple cell types (Hiroi et al. 2006, Kalyanaraman et al. 2014, Wrutniak-Cabello et al. 2017).

Studies in diverse cell types, including human adipose-derived stem cells (hADSC), human primary osteoblasts, mouse osteoblast-like MC3T3 cells, monkey kidney cells (CV-1), neonatal rat ventricular myocytes (NRVM), and mouse cardiomyocytes (HL-1), have revealed TR subtypes localized to the mitochondria, plasma membrane and cytoplasmic compartments in a tissue-specific manner (Carazo et al. 2012, Kalyanaraman et al. 2014, Cvoro et al. 2016, Wadosky et al. 2016). Of particular interest, human ADSCs are multipotent adult stem cells with the capacity to differentiate into adipocytes, chondrocytes and osteocytes, and they express TRα1, TRα2 and TRβ1 at variable levels. TR intracellular localization was investigated by indirect immunofluorescence assay and, interestingly, all subtypes showed cytoplasmic localization. Further examination via double immunostaining of TRα1 and TRα2 with a mitochondrial marker showed a predominantly mitochondrial localization for TRα1 proteins (Psarra & Sekeris 2008, Carazo et al. 2012, Wadosky et al. 2016). Although western blot analysis was not performed to visualize protein size, these findings suggest that truncated forms of TR were reliably being detected by the antibodies used in this study.

**Mitochondrial targeting**

A major compartment of thyroid hormone accumulation within the cell is the mitochondria (Bassett et al. 2003, Psarra & Sekeris 2008, Davis et al. 2016, Wrutniak-Cabello et al. 2017). The major effect of thyroid hormone on mitochondrial activity has been partially explained by reports of truncated TRα1 variants localizing to the mitochondria of different mammalian tissues, such as liver, brown and white adipose tissue, red and white muscle, heart, tongue and testis (Carazo et al. 2012, Fumel et al. 2013, Wrutniak-Cabello et al. 2017). In addition, a truncated TRβ (TR β1) localizes to the mitochondria in Xenopus laevis (South African clawed frog) oocytes (Saelim et al. 2007). TRα1 p43 is targeted to the mitochondrial matrix, while TRα1 p28 is targeted to the mitochondrial inner membrane (Carazo et al. 2012, Kalyanaraman et al. 2014, Wrutniak-Cabello et al. 2017) (Fig. 4). TRα1 p43 displays an N-terminal deletion that lacks NLS-2, but still possesses NLS-1 in the hinge region (Fig. 1). In contrast, TRα1 p28 displays an N-terminal deletion of the A/B domain, the DBD and NLS-1. Neither p43 nor p28 possesses a canonical mitochondrial import sequence (MIS). Nonetheless, sequences within helices 5, 10 and 11 in the C-terminal LBD of p43 and p28 have been identified that are necessary for mitochondrial import (Carazo et al. 2012) (Fig. 1). Helix 5,
spanning amino acids 242–252 of TRα1, was found to drive an atypical mitochondrial import process independent of ATP and the mitochondrial membrane potential; whereas helices 10–11, spanning amino acids 298–354, induced a typical mitochondrial import process sensitive to ATP and the mitochondrial membrane potential. Whether these two mitochondrial import sequences, MIS1 and MIS2, are functional or not, is proposed to depend on the ‘permissive’ role of the N-terminus of TRα1 (Carazo et al. 2012). In this model, conformational changes of the protein, dependent on the flexibility of the hinge region, would disrupt the functionality of NLS-1 in the hinge region and induce the activity of the mitochondrial import sequences (Wrutniak-Cabello et al. 2017). Interestingly, TRβ1 harbors these conserved MIS1 and MIS2 motifs and lacks NLS-2 in the N-terminal A/B domain (Fig. 1), but there is no evidence of functionality of the MIS motifs. It is of interest to determine the exact nature of the N-terminal A/B domain sequence in regulating localization of TRs to the mitochondrial or nuclear compartments.

**Plasma membrane targeting**

Beyond type 1 genomic actions within the mitochondria, type 3 actions of TR are primarily associated with its localization to the plasma membrane. The alternative translation product TRα1 p30 is targeted to the plasma membrane where it is proposed to play a key role in mediating signaling pathways involved in cell survival and proliferation (Carazo et al. 2012, Kalyanaraman...
et al. 2014, Wrutniak-Caballo et al. 2017). Further, there is tissue-specific variation in p30’s localization to the plasma membrane (Kalyanaraman et al. 2014). In murine primary osteoblasts, TRα1 p30 associates with lipid rafts (cholesterol-rich plasma membrane microdomains that contain caveolin-1) to function as a unique signal transduction platform. In contrast, in MC3T3 cells, TRα1 p30 associated with caveolin-1, nitric oxide synthase 3 (NOS3), protein kinase G type II (PKGII) and the tyrosine kinase Src. These data point to the possibility that TRα1 p28 localizes to the mitochondrial inner membrane following a similar mechanism (Kalyanaraman et al. 2014), and provide an understanding of how certain membrane-targeted proteins interact with caveolin to reach the plasma membrane (Hayer et al. 2010).

A role for post-translational modification in TR localization

Post-translational modifications (PTMs) play a significant role in the regulation of protein structure, enzymatic activity, stability or degradation, subcellular localization, protein–protein interactions and diverse cell signaling (Rodriguez 2014, Lin et al. 2015, Azevedo & Saiardi 2016, Drazic et al. 2016). Many amino acid side chains such as cysteine (C), serine (S), threonine (T) and tyrosine (Y) are post-translationally modified; however, the amino acid lysine (K) is targeted by an extremely high number of PTMs including methylation, ubiquitination, sumoylation and acetylation. Thyroid hormone receptors, and other nuclear receptors, undergo PTMs that influence transcriptional activity and subcellular localization (Cui et al. 2004, Lin et al. 2005, Sanchez-Pacheco et al. 2009, Abdel-Hafiz & Horwitz 2014, Faresse 2014). For example, the association of TRα1 p30 with the plasma membrane is mediated by palmitoylation, a post-translational lipid modification. Consequently, it has been predicted that cysteine (Cys)254 and Cys255 palmitoylation is necessary to localize p30 to the plasma membrane (Kalyanaraman et al. 2014).

For nuclear TRs, phosphorylation regulates DNA binding and transcriptional activation, and it has been shown that phosphorylation of one or more sites in TRα1 enhances nuclear retention or inhibits nuclear export but is not directly involved in nuclear import (Nicoll et al. 2003). Intriguingly, a recent study suggests the phosphorylation of TRβ1 may play a role in promoting nuclear localization in serum-starved Chinese hamster ovary (CHO) cells. FLAG-tagged TRβ1 was shown to form a cytoplasmic complex with the p85 regulatory subunit of PI3K and the Src family kinase Lyn (Martin et al. 2014). Complex formation was dependent on two phosphotyrosine motifs in the second zinc finger of TRβ1 that are not conserved in TRα1. When hormone was added, the complex dissociated, allowing PI3K activity to increase and TRβ1 to move into the nucleus to regulate transcription. It will be of interest to extend these studies to tracking receptor movement in live cells. The authors suggest that dramatic shifts in localization may not be observable with GFP-tagged receptors, because the GFP tag might interfere with PI3K association; however, their qualitative observations of receptor distribution are consistent with the variability we see in populations of cells expressing GFP-TRβ1. As shown in Fig. 3, GFP-TRβ1 typically has a greater cytosolic population than GFP-TRα1, and we find TRβ1 distributions ranging from whole cell to primarily nuclear. For critical analysis of the fine nuances of receptor localization, rigorous quantification of the nucleus vs cytoplasmic distribution by fluorescence intensity measurements will be essential.

Acetylation sites that are important for transcriptional activity have been identified in the hinge domain of TR, corresponding to K130, K134 and K136 in human TRα1 (Sanchez-Pacheco et al. 2009), and to K184, K188 and K190 in TRβ1 (Lin et al. 2005). These lysines are integral components of NLS-1 (Mavinakere et al. 2012), suggesting that acetylation state could have an impact on NLS activity. Whether this PTM is important for modulating the nuclear localization of TR subtypes is under investigation.

It is known that ubiquitination of liganded TRα1 targets the receptor for rapid proteasome-mediated degradation (Bondzi et al. 2011). Recently, it was reported that monoubiquitination of TRα1 within its LBD results in a shift in the diffuse intranuclear localization of TRα1 toward the nuclear periphery in cardiomyocytes (Wadosky et al. 2016). TRα1 activity stimulates hypertrophy in cardiomyocytes, and although TRα2 and TRβ1 are present in this cell type, they lack this function. Muscle-specific ubiquitin ligase muscle ring finger-1 (MuRF1) (Rodriguez et al. 2015) was shown to monoubiquitinate TRα1 in vitro; however, specific lysine sites have not yet been identified and monoubiquitinated forms have not been detected in vivo (Wadosky et al. 2016). Whether polyubiquitination or monoubiquitination directly modulates TR nucleocytoplasmic shuttling remains to be determined.

Several studies have provided evidence that sumoylation of TR plays an essential role in fine-tuning TR regulation of gene expression. SUMO modification
sites have been identified at K283 and K389 of TRα1 (positioned in NES-H3/H6); and at K50 (A/B domain within AF-1), K146 (DBD) and at K443 (near the NES-H12 motif) of TRβ1 (Liu et al. 2012, 2015, Weitzel 2016). Given the proximity of the SUMO-modified lysines to NES motifs, sumoylation is also under study for its impact on NES activity and TR nuclear localization.

Taken together, these reports provide insights into the possible interplay of TR post-translational modification with TR localization: palmitoylation directs p30 to the membrane; phosphorylation promotes nuclear retention; acetylation occurs within the hinge NLS-1 and ubiquitination and sumoylation occur within the NES-containing LBD of TR. Although not yet reported to be post-translationally modified, TRα1 p43 contains mitochondrial import sequences and thus has a high probability of also containing PTM sites that modulate trafficking.

Mislocalization of thyroid hormone receptors and disease

In addition to diseases correlated with dysregulated hormone production, mutations in TR can give rise to disease, most notably the autosomal dominant resistance to thyroid hormone (RTH) syndrome; and mutations can contribute to certain types of cancer, including human hepatocellular carcinoma, renal clear cell carcinoma, breast cancer, pituitary tumor and thyroid cancer (Astashova et al. 2011). Early evidence to suggest that mutated TR could be involved in carcinogenesis came from the discovery that TRα1 is the cellular counterpart of the retroviral v-ErbA carried by the avian erythroblastosis virus involved in acute erythroleukemia and sarcomas (Sap et al. 1986). Many of these TR mutants have lost T₃ binding and transactivation capacity and some exhibit dominant negative activity (Conde et al. 2006, Martinez-Iglesias et al. 2009, Rosen & Privalsky 2009, 2011, Chan & Privalsky 2010, Rosen et al. 2011, Kim & Cheng 2013, Lin et al. 2013, Wojcicka et al. 2014). The question is thus raised, does receptor localization impact disease pathology? So far, the answer appears to be, yes. Dominant negative TR mutants, such as v-ErbA, have been shown to localize to both the nuclear and cytoplasmic compartments in cells (Boucher et al. 1988), are recruited to aggresomes, display altered transport activity and mislocalize TRα1 to these cytosolic inclusions (Bunn et al. 2001, DeLong et al. 2004, Bonamy et al. 2005, Bonamy & Allison 2006, Bondzi et al. 2011, Takalo et al. 2013, Zhang et al. 2018). The altered localization of v-ErbA appears to be enhanced by acquisition of the N-terminal viral Gag sequence, which harbors a strong CRM1-dependent NES (DeLong et al. 2004).

The factors that determine whether a given amino acid substitution causes endocrine disruption or cancer remain enigmatic, particularly for changes within the LBD. Typically, human cancers have multiple TR mutations, while single mutations are characteristic of RTH, and it has been proposed that synergistic interactions of these mutations strengthen the dominant negative activity (Rosen & Privalsky 2009, 2011). RTH syndromes exist due to mutations in the respective TR isoforms, TRα1 and TRβ1, and the variability in symptomatic phenotype is characterized by the tissues in which these isoforms are highly expressed (Mullur et al. 2014, Vella et al. 2014, Mendoza & Hollenberg 2017, Vella & Hollenberg 2017). Clinical phenotypes of RTH include elevated thyroid hormone levels, goiter, short stature, decreased weight, tachycardia, hearing loss, attention-deficit hyperactivity disorder, decreased IQ and dyslexia (Parrilla et al. 1991, Bochukova et al. 2012, Dumitrescu & Refetoff 2013, Moran et al. 2013, Schoenmakers et al. 2013). Interestingly, the highest frequency of mutations occurs in the region corresponding to NES-H12, with another cluster of mutations occurring within NES-H3/H6 (Fig. 1).

Except for our prior studies, there is little information on the contribution of altered nucleocytoplasmic shuttling dynamics to the phenotype of RTH and cancer-promoting mutants. Two of our recent findings stand out: a R26H substitution in NLS-2 of the oncoprotein v-ErbA abrogates the activity of NLS-2, while mutagenesis studies on NES-H12 point to the intriguing possibility that altered shuttling of TRβ1 may be a contributing factor in RTH (Mavinakere et al. 2012). Based on these data, we hypothesize that intracellular mislocalization of TR is a crucial factor to consider in pathogenesis (Bonamy et al. 2005, Bonamy & Allison 2006).

Concluding remarks

Thyroid hormone receptor subtypes mediate the actions of thyroid hormone in a variety of cellular compartments, including the nucleus, the mitochondria and at the inner surface of the plasma membrane (Fig. 4). Within the nucleus, TRα1 and TRβ1 bind to the TREs of target genes, in the presence or absence of thyroid hormone, to influence an astonishing number of cellular processes,
including cell proliferation, oxygen consumption, protein synthesis and carbohydrate, lipid and vitamin metabolism. The physiological significance of TRα1 and TRβ1 nucleocytoplasmic shuttling may, at least in part, be to serve as a ‘ferry boat’ (Kolodkin et al. 2010) to increase the rate of T₃ (and possibly T₂) nuclear entry, relative to simple diffusion through the cytosol, or to circumvent localization of T₃ to the mitochondria. Furthermore, important PTMs have been reported that suggest an increasingly complex interplay with TR’s NLS and NES motifs, and possibly MIS motifs, which may affect TR’s ultimate localization in target tissues. There is a dynamic balance between nuclear import, retention and export of shuttling transcription factors and, in the case of TR, localization to cytoplasmic compartments as well. These observations, coupled with the multiplicity of thyroid hormone signaling within the cell, may provide important insights into the development of treatments for RTH and some types of cancer.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This work was supported in part by National Institutes of Health grant 2R15DK058028 and National Science Foundation grant MCB 1120513 to L A A.

References
Apostolakos I & Hollenberg AN 2013 The in vivo role of nuclear receptor corepressors in thyroid hormone action. Biochimica et Biophysica Acta 1830 3876–3881. (https://doi.org/10.1016/j.bbadis.2012.07.001)
Azevedo C & Saiardi A 2016 Why always lysine? The ongoing tale of one of the most modified amino acids. Advances in Biological Regulation 60 144–150. (https://doi.org/10.1016/j.bior.2015.09.008)
Bonamy GM & Allison LA 2006 Oncogenic conversion of the thyroid hormone receptor by altered nuclear transport. Nuclear Receptor Signaling 4 e008. (https://doi.org/10.1612/nrs.00408)
Bonamy GM, Guiotchon-Mantel A & Allison LA 2005 Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors. Molecular Endocrinology 19 1213–1230. (https://doi.org/10.1210/me.2004-0204)
Brent GA 2012 Mechanisms of thyroid hormone action. Journal of Clinical Investigation 122 3035–3043. (https://doi.org/10.1172/JCI60047)
Buchholz DR, Paul BD, Fu L & Shi YB 2006 Molecular and developmental analyses of thyroid hormone receptor function in Xenopus laevis, the African clawed frog. General and Comparative Endocrinology 145 1–19. (https://doi.org/10.1016/j.ygcen.2005.07.009)
Bunn CF, Neidig JA, Freidinger KE, Stankiewicz TA, Weaver BS, McGrew J & Allison LA 2001 Nucleocytoplasmic shuttling of the thyroid hormone receptor α. Molecular Endocrinology 15 512–533. (https://doi.org/10.1210/mend.15.4.0619)
Thyroid hormone receptors α variant involved in the regulation of myoblast differentiation. Molecular Endocrinology 20 749–763. (https://doi.org/10.1210/me.2005-0074)


Chan IH & Privalsky ML 2010 A conserved lysine in the thyroid hormone receptor-α DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation. Molecular Cancer Research 8 15–23. (https://doi.org/10.1158/1541-7766.MCR-09-0425)


Dumitrescu AM & Refetoff S 2013 The syndromes of reduced sensitivity to thyroid hormone. Biochimica et Biophysica Acta 1830 3987–4003. (https://doi.org/10.1016/j.bbagen.2012.08.005)


Flamant F & Gauthier K 2013 Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. Biochimica et Biophysica Acta 1830 3900–3907. (https://doi.org/10.1016/j.bbagen.2012.06.003)


common theme. Current Opinion in Cell Biology 46 110–118. (https://doi.org/10.1016/jceb.2017.05.003)


Helbing CC, Crump K, Bailey CM, Kohno S, Veldhoen N, Bryan T, Bermudez D & Guillette LJ Jr 2006 Isolation of the allergist (Alligator mississippiensis) thyroid hormone receptor α and β transcripts and their responsiveness to thyroid stimulating hormone. General and Comparative Endocrinology 149 141–150. (https://doi.org/10.1016/j.ygcen.2006.05.019)


Huang W, Xu F, Qu T, Zhang R, Li L, Que H & Zhang G 2015 Identification of thyroid hormones and functional characterization of thyroid hormone receptor in the Pacific Oyster Crassostrea gigas provide insight into evolution of the thyroid hormone system. PLoS ONE 10 e0144991. (https://doi.org/10.1371/journal.pone.0144991)


Lin HY, Kogal T, Schultz JJ, Mosy K & Brent GA 2012 Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation. Journal of Biological Chemistry 287 36499–36508. (https://doi.org/10.1074/jbc.M112.444317)


Manzon LA, Youson JH, Holzer G, Staiano L, Laudet V & Manzon RG 2014 Thyroid hormone and retinoid X receptor function and expression during sea lamprey (Petromyzon marinus) metamorphosis. General and Comparative Endocrinology 204 211–222. (https://doi.org/10.1016/j.ygcen.2014.05.030)


McKenna NJ, Lanz RB & O’Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321–344. (https://doi.org/10.1210/edrv.20.3.0366)


2017 NCoR1-independent mechanism plays a role in the action of the unliganded thyroid hormone receptor. PNAS 114 E8458–E8467. (https://doi.org/10.1073/pnas.1706917114)


Moriyama K, Yamamoto H, Futawaka K, Atake A, Kasahara M & Tagami T 2016 Molecular characterization of human thyroid hormone receptor β isoform 4. Endocrine Research 41 34–42. (https://doi.org/10.1016/j.endcr.2015.06.008)


Nascimento AS, Dias SM, Santos MA, de Oliveira Neto M, Fischer H, et al. 2006 Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. Journal of Molecular Biology 360 586–598. (https://doi.org/10.1016/j.jmb.2006.05.008)


Oberste-Berghaus C, Zanger K, Hashimoto K, Cohen RN, Hollenberg AN & Wondisford FE 2000 Thyroid hormone-independent interaction between the thyroid hormone receptor β2 amino terminus and coactivators. Journal of Biological Chemistry 275 1787–1792. (https://doi.org/10.1074/jbc.275.3.1787)

Orozco A, Navarrete-Ramirez P, Olivera A & Garcia GC 2014 3,5-Diiodothyronine (T2) is on a role. A new hormone in search of its target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Molecular Endocrinology 25 1311–1325. (https://doi.org/10.1210/me.2010-0420)


Roggero VR, Zhang J, Parente LE, Doshi Y, Dziedzic RC, McGregor EL, Varjabedian AD, Schad SE, Bondzi C & Allison LA 2016 Nuclear import of the thyroid hormone receptor α1 is mediated by importin 7, importin β1, and adaptor importin α1. Molecular and Cellular Endocrinology 419 185–197. (https://doi.org/10.1016/j.mce.2015.10.016)

Rosen MD & Privalsky ML 2009 Thyroid hormone receptor mutations found in renal clear cell carcinomas alter coexpressor release and reveal helix 12 as key determinant of coexpressor specificity. Molecular Endocrinology 23 1183–1192. (https://doi.org/10.1210/me.2009-0126)


Rosen MD, Chan IH & Privalsky ML 2011 Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Molecular Endocrinology 25 1311–1325. (https://doi.org/10.1210/me.2010-0420)


Saelim N, Holstein D, Chocron ES, Camacho P & Lechleiter JD 2007 Inhibition of apoptotic potency by ligand stimulated thyroid hormone receptors located in mitochondria. Apoptosis 12 1781–1794. (https://doi.org/10.1007/s10495-007-0109-1)


Schoenmakers N, Moran C, Peeters RP, Visser T, Gurnell M & Chatterjee K 2013 Resistance to thyroid hormone mediated by defective thyroid hormone receptor α. Biochimica et Biophysica Acta 1830 4004–4008. (https://doi.org/10.1016/j.bbagen.2013.03.018)


Soriano FX, Leveille F, Papadia S, Bell KE, Puffodt C & Hardinghe GE 2011 Neuronal activity controls the antagonistic balance between peroxisome proliferator-activated receptor-γ coactivator-1α and silencing mediator of retinoic acid and thyroid hormone receptors in regulating antioxidant defenses. Antioxidants and Redox Salvaging 14 1425–1436. (https://doi.org/10.1098/rars.2010.3568)


Tomura H, Lazar J, Phyllaiher M & Nikodem VM 1995 The N-terminal region (A/B) of rat thyroid hormone receptors α 1, β 1, but not β 2 contains a strong thyroid hormone-dependent transactivation function. PNAS 92 5600–5604. (https://doi.org/10.1073/pnas.92.12.5600)

Tran EJ, King MC & Corbett AH 2014 Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease. Biochimica et Biophysica Acta 1843 2784–2795. (https://doi.org/10.1016/j.bbamcr.2014.08.003)


Wadovsky KM, Berthiaume JM, Tang W, Zangui M, Portman MA, Gerdes AM & Willis MS 2016 MuRF1 mono-ubiquitinites TRβs to inhibit T3-induced cardiac hypertrophy in vivo. Journal of Molecular Endocrinology 56 273–290. (https://doi.org/10.1038/jme.2015.0285)


Weitzel JM 2016 Impaired repressor function in SUMOylation-defective thyroid hormone receptor isoforms. European Thyroid Journal 5 152–163. (https://doi.org/10.1159/000447232)


